{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:11:17Z","timestamp":1740107477268,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T00:00:00Z","timestamp":1559520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00535-019-01595-5","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T19:02:43Z","timestamp":1559588563000},"page":"829-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma"],"prefix":"10.1007","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8059-8433","authenticated-orcid":false,"given":"Kazuyuki","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,3]]},"reference":[{"key":"1595_CR1","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/NEJM199903113401001","volume":"340","author":"HB El-Serag","year":"1999","unstructured":"El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745\u201350.","journal-title":"N Engl J Med"},{"key":"1595_CR2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compemsated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463\u201372.","journal-title":"Gastroenterology"},{"key":"1595_CR3","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(03)15109-4","volume":"362","author":"T Poynard","year":"2003","unstructured":"Poynard T, Yuen MF, Ratziu V, et al. Viral hepatitis C. Lancet. 2003;362:2095\u2013100.","journal-title":"Lancet"},{"key":"1595_CR4","doi-asserted-by":"publisher","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","volume":"127","author":"P Marcellin","year":"1997","unstructured":"Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875\u201381.","journal-title":"Ann Intern Med"},{"key":"1595_CR5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/hep.510260335","volume":"26","author":"ML Shiffman","year":"1997","unstructured":"Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997;26:780\u20135.","journal-title":"Hepatology"},{"key":"1595_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517\u201324.","journal-title":"Ann Intern Med"},{"key":"1595_CR7","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124\u201330.","journal-title":"Hepatology"},{"key":"1595_CR8","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7326\/0003-4819-129-2-199807150-00005","volume":"129","author":"Y Imai","year":"1998","unstructured":"Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129:94\u20139.","journal-title":"Ann Intern Med"},{"key":"1595_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"1595_CR10","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hep.510270529","volume":"27","author":"A Kasahara","year":"1998","unstructured":"Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394\u2013402.","journal-title":"Hepatology"},{"key":"1595_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","volume":"58","author":"E Ogawa","year":"2013","unstructured":"Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective multicenter study. J Hepatol. 2013;58:495\u2013501.","journal-title":"J Hepatol"},{"key":"1595_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jhep.2016.11.012","volume":"66","author":"H Toyoda","year":"2017","unstructured":"Toyoda H, Kumada T, Tada T, et al. Efficacy and tolerability of an IFN-free regimen with DCV\/ASV for elderly patients infected with HCV genotype 1B. J Hepatol. 2017;66:521\u20137.","journal-title":"J Hepatol"},{"key":"1595_CR13","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1111\/hepr.12738","volume":"47","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Yamashita N, et al. Effectiveness and safety of daclatasvir plus asunapre-vir for HCV genotype 1b patients aged 75 and over with or without cirrhosis. Hepatol Res. 2017;47:E120\u2013E131131.","journal-title":"Hepatol Res"},{"key":"1595_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1007\/s00535-016-1255-4","volume":"52","author":"R Morio","year":"2017","unstructured":"Morio R, Imamura M, Kawakami Y, et al. Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. J Gastroenterol. 2017;52:504\u201311.","journal-title":"J Gastroenterol"},{"key":"1595_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jmv.24592","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 2017;89:91\u20138.","journal-title":"J Med Virol"},{"key":"1595_CR16","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/apt.13769","volume":"44","author":"J Vermehren","year":"2016","unstructured":"Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug\u2013drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44:856\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"1595_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jhep.2016.12.012","volume":"66","author":"R Vukotic","year":"2017","unstructured":"Vukotic R, Conti F, Andreone P. Hepatitis C virus eradication in the elderly: the challenge worth a long-life elixir? J Hepatol. 2017;66:476\u20137.","journal-title":"J Hepatol"},{"key":"1595_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"1595_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hep.1840200104","volume":"20","author":"The French METAVIR Cooperative Study Group","year":"1994","unstructured":"The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15\u201320.","journal-title":"Hepatology"},{"key":"1595_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology"},{"key":"1595_CR21","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol"},{"key":"1595_CR22","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc."},{"key":"1595_CR23","unstructured":"Ministry of Health, Labor and Welfare in Japan. \n                    https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/life\/22th\/index.html\n                    \n                  . Accessed 6 Nov 2018."},{"key":"1595_CR24","unstructured":"Statistics Bureau, Ministry of Internal Affairs and Communications in Japan. \n                    https:\/\/www.stat.go.jp\/index.html\n                    \n                  . Accessed 8 Jan 2019."},{"key":"1595_CR25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000324525","volume":"54","author":"J Tanaka","year":"2011","unstructured":"Tanaka J, Koyama T, Mizui M, et al. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011;54:185\u201395.","journal-title":"Intervirology"},{"key":"1595_CR26","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1017\/S0950268814000478","volume":"142","author":"H Toyoda","year":"2014","unstructured":"Toyoda H, Kumada T, Takaguchi K, et al. Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect. 2014;142:2624\u20138.","journal-title":"Epidemiol Infect"},{"key":"1595_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/hep.23691","volume":"52","author":"Y Asahina","year":"2010","unstructured":"Asahina Y, Tsuchiya K, Tamaki N, et al. Effect of aging on risk of hepatocellular carcinoma in cirrhotic hepatitis C virus infection. Hepatology. 2010;52:518\u201327.","journal-title":"Hepatology"},{"key":"1595_CR28","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/jgh.12057","volume":"28","author":"T Kumada","year":"2013","unstructured":"Kumada T, Toyoda H, Kiriyama S, et al. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients. J Gastroenterol Hepatol. 2013;28:357\u201364.","journal-title":"J Gastroenterol Hepatol"},{"key":"1595_CR29","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"A Van der Meer","year":"2012","unstructured":"Van der Meer A, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584\u201393.","journal-title":"JAMA"},{"key":"1595_CR30","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/liv.13071","volume":"36","author":"T Tada","year":"2016","unstructured":"Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016;36:817\u201326.","journal-title":"Liver Int"},{"key":"1595_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/cam4.1909","volume":"8","author":"A Hiraoka","year":"2019","unstructured":"Hiraoka A, Kumada T, Kariyama K, et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med. 2019;8:137\u201346.","journal-title":"Cancer Med."}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01595-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-019-01595-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-019-01595-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:50:42Z","timestamp":1591059042000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-019-01595-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,3]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1595"],"URL":"https:\/\/doi.org\/10.1007\/s00535-019-01595-5","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"type":"print","value":"0944-1174"},{"type":"electronic","value":"1435-5922"}],"subject":[],"published":{"date-parts":[[2019,6,3]]},"assertion":[{"value":"27 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}